Menopausal Hot Flashes Market Size, Share & Forecast to 2030

The Menopausal Hot Flashes Market grew from USD 8.64 billion in 2024 to USD 9.20 billion in 2025. It is expected to continue growing at a CAGR of 6.42%, reaching USD 12.55 billion by 2030.

Introduction to the Evolving Landscape of Menopausal Symptom Management

As women navigate the transition into menopause, hot flashes remain one of the most disruptive symptoms, affecting daily routines, sleep patterns, and emotional wellness. Epidemiological data suggest that a significant majority of perimenopausal and postmenopausal women experience vasomotor symptoms, prompting growing demand for effective therapeutic solutions. This environment has spurred innovation across complementary, hormonal, and non-hormonal modalities, reflecting an industry-wide shift toward tailored patient care.

This executive summary distills the most critical developments shaping the menopausal hot flashes landscape. It highlights transformative trends in treatment paradigms, analyzes the cumulative effects of recent policy measures, and explores key segmentation insights across product types, distribution channels, and demographic cohorts. Readers will also gain regional perspectives, competitive analysis of leading players, actionable recommendations for market leadership, and an overview of the rigorous research methodology underpinning these insights.

By synthesizing these elements, this document equips decision makers with the clarity and context needed to navigate a rapidly evolving market. Strategic initiatives grounded in this analysis will be better positioned to address unmet needs, optimize resource allocation, and capitalize on emerging opportunities within the menopausal hot flashes domain.

Emerging Paradigm Shifts Reshaping Treatment Modalities

The menopausal hot flashes market is undergoing profound transformation as stakeholders embrace novel treatment approaches and delivery mechanisms. Demographic shifts-particularly the growing population of women entering perimenopause-are driving both volume growth and diversification in therapeutic preferences. Concurrently, patient expectations have evolved, with an emphasis on personalized regimens that balance efficacy, safety, and quality of life.

Technological advancements in digital health platforms and telemedicine have further reshaped patient engagement models, enabling remote monitoring of symptom severity and adherence patterns. This fusion of digital and clinical care is broadening the scope of evidence generation, allowing real-time insights into treatment outcomes. Moreover, integrative medicine is gaining traction as holistic frameworks combine herbal extracts, micronutrients, and mind-body interventions to complement traditional pharmacological therapies.

Regulatory landscapes are also shifting, as agencies worldwide reevaluate risk-benefit profiles for hormone-based formulations and non-hormonal alternatives. Emerging guidelines emphasize long-term safety surveillance and real-world evidence, reinforcing a patient-centric approach. Together, these factors constitute a paradigm shift in how menopausal hot flashes are understood, diagnosed, and managed, setting the stage for dynamic market evolution.

Navigating the Effects of 2025 United States Tariff Policies

In 2025, the implementation of revised United States tariffs has introduced new cost dynamics for manufacturers and distributors of menopausal therapies. Increased duties on imported raw materials, including plant-derived extracts and specialized polymers used in transdermal systems, have heightened production expenses. These incremental costs have, in many cases, been transferred along the supply chain, challenging pricing strategies and reimbursement negotiations.

Domestic manufacturing capacities are expanding as companies seek to mitigate tariff exposure by reshoring critical production processes. While this transition supports supply chain resilience and quality control, it also requires substantial capital investment and process optimization to match the scale of established international facilities. Moreover, regulatory compliance for facilities repatriated under tariff-driven restructuring demands rigorous validation and certification, extending time-to-market for new or reformulated products.

Longer-term implications include potential shifts in global sourcing alliances and the emergence of regional supply hubs. Stakeholders are reevaluating tariff pass-through and absorption models to maintain competitive positioning without compromising affordability for end users. This recalibration underscores the necessity of agile procurement strategies and strategic partnerships to navigate the evolving tariff environment.

Uncovering Core Patient and Product Segmentation Dynamics

Comprehensive segmentation analysis reveals distinct patterns in product adoption and patient preferences. Within complementary therapy, formulations containing Black Cohosh, Dong Quai, and isoflavones demonstrate sustained appeal among individuals seeking plant-based relief. Hormonal therapy remains anchored by combined estrogen-progestin regimens, while standalone estrogen options-spanning oral, topical, and transdermal delivery-cater to varying safety profiles and convenience requirements. Selective estrogen receptor modulators have carved a niche for patients who benefit from targeted receptor activity, and non-hormonal alternatives such as clonidine and gabapentin address needs for non-endocrine pathways. The selective serotonin reuptake inhibitors fluoxetine, paroxetine, and sertraline represent an additional segment for women prioritizing mood stabilization and vasomotor control.

Distribution channels exhibit nuanced dynamics, with clinics maintaining a key role in initial diagnosis and therapy initiation, while private and public hospital pharmacies fulfill high-volume prescriptions for complex formulations. Meanwhile, company websites and e-commerce platforms are capturing a growing share of self-directed purchases, particularly for over-the-counter and complementary products. Demographically, the 40 to 50 cohort shows a propensity for lifestyle-oriented solutions, the 51 to 60 group drives demand for clinically validated therapies, and the above-60 segment values convenience offered by transdermal and oral administration. These layered insights enable targeted engagement strategies and product positioning aligned with patient needs and channel characteristics.

Regional Market Nuances Driving Strategic Priorities

Geographic performance underscores divergent growth trajectories and strategic imperatives. In the Americas, robust reimbursement frameworks and high patient awareness fuel strong uptake of both hormonal and non-hormonal therapies, while integrated care pathways support multidisciplinary treatment models. Europe, Middle East & Africa present a mosaic of markets: Western European nations demonstrate high penetration of advanced delivery systems and evidence-based protocols, whereas emerging economies across the region rely more heavily on complementary therapies and face variable regulatory harmonization. In Asia-Pacific, rapid healthcare investment in key markets such as China, Japan, and Australia is bolstering clinical adoption rates, with cultural affinity for herbal remedies reinforcing demand for phytoestrogen-rich interventions.

Regional regulatory reforms are further shaping market entry strategies, as accelerated approvals for innovative formulations incentivize early investment. Simultaneously, logistical considerations-ranging from cold-chain integrity for temperature-sensitive products to last-mile distribution in remote areas-drive localized supply chain adaptations. Recognizing these regional nuances is essential for designing tailored go-to-market approaches and forging collaborative partnerships with local stakeholders.

Evaluating Leading Players and Competitive Strategies

Leading organizations in the menopausal hot flashes segment are demonstrating diverse competitive strategies. Global pharmaceutical corporations are leveraging extensive R&D capabilities to refine hormone therapies with optimized safety profiles and user-friendly delivery formats. Simultaneously, specialized biotechs and contract research entities are advancing novel non-hormonal candidates, investing in pharmacogenomic screenings to personalize treatment regimens.

Collaborative alliances are reshaping the competitive terrain, as companies form joint ventures with digital health firms to integrate symptom tracking applications and teleconsultation services. Portfolio diversification remains a priority, with several players acquiring or licensing complementary product lines to capture broader market share. Exclusive distribution agreements in key geographies are securing channel access, while strategic partnerships with academic research centers enable accelerated clinical trials and real-world evidence generation.

Additionally, companies are piloting value-based pricing models in collaboration with payers, linking reimbursement to demonstrable improvements in patient-reported outcomes. By aligning commercial strategies with evolving healthcare economics, these organizations are positioning themselves to thrive amidst shifting payer priorities and patient expectations.

Strategic Recommendations to Capitalize on Market Opportunities

To capitalize on emerging opportunities, industry leaders should prioritize multifaceted action plans. First, investment in personalized medicine initiatives-enabled by pharmacogenomic profiling and digital symptom monitoring-will enhance therapeutic efficacy and patient satisfaction. Second, expanding domestic manufacturing capabilities can offset tariff risks and support agile supply chain management, ensuring continuity of access.

Third, forging partnerships with integrative health practitioners and wellness platforms will broaden market penetration for complementary therapies. Fourth, embedding patient engagement tools within clinical workflows will drive adherence and real-world data capture, strengthening value propositions to payers. Fifth, adopting value-based contracts that tie reimbursement to symptom reduction and quality of life metrics will align stakeholder incentives and demonstrate cost-effectiveness.

Finally, tailoring regional launch plans to local regulatory frameworks and cultural preferences will maximize uptake. By integrating these recommendations into strategic roadmaps, organizations can secure competitive differentiation, foster sustainable growth, and improve patient outcomes across the menopausal hot flashes spectrum.

Robust Methodological Framework Underpinning the Analysis

This analysis is grounded in a robust methodological framework designed to ensure rigor and validity. Primary research comprised in-depth interviews with gynecologists, endocrinologists, pharmacists, payer representatives, and patient advocacy groups, providing nuanced insights into clinical practice patterns and unmet needs. Secondary research involved exhaustive review of peer-reviewed journals, regulatory submissions, proprietary databases, and industry white papers to triangulate quantitative and qualitative data.

Data validation processes included cross-verification of market figures, segmentation analyses, and geographic breakdowns against multiple independent sources. Sensitivity analyses assessed the impact of variable assumptions on key findings, while expert panel reviews offered critical peer validation. The segmentation framework was developed based on prescribing trends, distribution channel dynamics, and demographic consumption patterns. Geographic clusters align with standard regional definitions, facilitating comparative analysis.

A structured quality control protocol ensured consistency in terminology, statistical accuracy, and adherence to research objectives. Limitations, such as data availability in select markets and evolving regulatory landscapes, were transparently documented to contextualize findings.

Synthesizing Insights to Inform Decision Making

The menopausal hot flashes landscape is at a pivotal juncture, driven by demographic growth, evolving patient preferences, technological innovation, and shifting policy frameworks. Complementary, hormonal, and non-hormonal therapies each have distinct roles within holistic care pathways, and segmentation insights reveal targeted avenues for product differentiation and channel optimization. Regional variations in regulatory environments and healthcare infrastructure further underscore the importance of localized strategies.

Competitive dynamics are intensifying, with established pharmaceutical players, nimble biotechs, and digital health entrants vying for market share. Those who harness the full spectrum of market intelligence-from tariff implications to patient segmentation nuances-will secure a decisive advantage. Actionable recommendations emphasize personalized approaches, strategic partnerships, value-based contracting, and resilient supply chain models as critical success factors.

By integrating these insights, stakeholders can refine strategic priorities, allocate resources more effectively, and deliver superior patient experiences. This synthesis serves as a guiding framework for decision makers committed to leading the next wave of innovation in menopausal hot flashes management.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

Product Type
- Complementary Therapy
  - Black Cohosh
  - Dong Quai
  - Isoflavones
- Hormonal Therapy
  - Combined Estrogen-Progestin Therapy
  - Estrogen Therapy
    - Oral Estrogen
    - Topical Estrogen
    - Transdermal Estrogen
  - Selective Estrogen Receptor Modulators
- Non-Hormonal Therapy
  - Clonidine
  - Gabapentin
  - SSRIs
    - Fluoxetine
    - Paroxetine
    - Sertraline
Distribution Channel
- Clinics
- Hospital Pharmacies
  - Private Hospitals
  - Public Hospitals
- Online Retailers
  - Company Websites
  - E-Commerce Platforms
Age Group
- 40 To 50
- 51 To 60
- Above 60

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

Americas
- United States
  - California
  - Texas
  - New York
  - Florida
  - Illinois
  - Pennsylvania
  - Ohio
- Canada
- Mexico
- Brazil
- Argentina
Europe, Middle East & Africa
- United Kingdom
- Germany
- France
- Russia
- Italy
- Spain
- United Arab Emirates
- Saudi Arabia
- South Africa
- Denmark
- Netherlands
- Qatar
- Finland
- Sweden
- Nigeria
- Egypt
- Turkey
- Israel
- Norway
- Poland
- Switzerland
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Indonesia
- Thailand
- Philippines
- Malaysia
- Singapore
- Vietnam
- Taiwan

This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:

AbbVie Inc.
Pfizer Inc.
Bayer AG
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
GlaxoSmithKline plc
Novartis AG
Amgen Inc.
Astellas Pharma Inc.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights

6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Menopausal Hot Flashes Market, by Product Type

8.1. Introduction
8.2. Complementary Therapy
8.2.1. Black Cohosh
8.2.2. Dong Quai
8.2.3. Isoflavones
8.3. Hormonal Therapy
8.3.1. Combined Estrogen-Progestin Therapy
8.3.2. Estrogen Therapy
8.3.2.1. Oral Estrogen
8.3.2.2. Topical Estrogen
8.3.2.3. Transdermal Estrogen
8.3.3. Selective Estrogen Receptor Modulators
8.4. Non-Hormonal Therapy
8.4.1. Clonidine
8.4.2. Gabapentin
8.4.3. SSRIs
8.4.3.1. Fluoxetine
8.4.3.2. Paroxetine
8.4.3.3. Sertraline

9. Menopausal Hot Flashes Market, by Distribution Channel

9.1. Introduction
9.2. Clinics
9.3. Hospital Pharmacies
9.3.1. Private Hospitals
9.3.2. Public Hospitals
9.4. Online Retailers
9.4.1. Company Websites
9.4.2. E-Commerce Platforms

10. Menopausal Hot Flashes Market, by Age Group

10.1. Introduction
10.2. 40 to 50
10.3. 51 to 60
10.4. Above 60

11. Americas Menopausal Hot Flashes Market

11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina

12. Europe, Middle East & Africa Menopausal Hot Flashes Market

12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland

13. Asia-Pacific Menopausal Hot Flashes Market

13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan

14. Competitive Landscape

14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. AbbVie Inc.
14.3.2. Pfizer Inc.
14.3.3. Bayer AG
14.3.4. Merck & Co., Inc.
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.6. Mylan N.V.
14.3.7. GlaxoSmithKline plc
14.3.8. Novartis AG
14.3.9. Amgen Inc.
14.3.10. Astellas Pharma Inc.

15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix

List of Figures

FIGURE 1. MENOPAUSAL HOT FLASHES MARKET MULTI-CURRENCY
FIGURE 2. MENOPAUSAL HOT FLASHES MARKET MULTI-LANGUAGE
FIGURE 3. MENOPAUSAL HOT FLASHES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. MENOPAUSAL HOT FLASHES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. MENOPAUSAL HOT FLASHES MARKET, FPNV POSITIONING MATRIX, 2024

List of Tables

TABLE 1. MENOPAUSAL HOT FLASHES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 69. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 70. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 72. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 74. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 75. CANADA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 129. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 130. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 131. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 132. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 139. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 140. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 141. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 142. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 145. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 159. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 160. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 161. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 162. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 163. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 165. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 166. ITALY MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 167. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 169. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 170. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 171. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 176. SPAIN MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 209. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 210. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 211. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 215. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 216. DENMARK MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 227. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 229. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 230. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 231. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 232. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 233. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 235. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 236. QATAR MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 239. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 240. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 241. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 245. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 269. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 270. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 271. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 279. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 280. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 281. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 282. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 285. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 286. TURKEY MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 297. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 298. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 299. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 300. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 301. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 302. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 305. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 307. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 308. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 309. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 310. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 311. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 312. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 313. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 315. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2030 (USD MILLION)
TABLE 316. POLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 317. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2030 (USD MILLION)
TABLE 319. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 320. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND MENOPAUSA

Companies Mentioned

The companies profiled in this Menopausal Hot Flashes market report include:

AbbVie Inc.
Pfizer Inc.
Bayer AG
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
GlaxoSmithKline plc
Novartis AG
Amgen Inc.
Astellas Pharma Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	184
Published	May 2025
Forecast Period	2025 - 2030
Estimated Market Value ( USD ) in 2025	$ 9.2 Billion
Forecasted Market Value ( USD ) by 2030	$ 12.55 Billion
Compound Annual Growth Rate	6.4%
Regions Covered	Global
No. of Companies Mentioned	11

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3245EUR$3,545USD£2,721GBP €3606EUR$3,939USD£3,024GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3501EUR$3,824USD£2,935GBP €3890EUR$4,249USD£3,262GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4745EUR$5,183USD£3,979GBP €5272EUR$5,759USD£4,421GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5742EUR$6,272USD£4,815GBP €6379EUR$6,969USD£5,349GBP

Menopausal Hot Flashes Market by Product Type, Distribution Channel, Age Group - Global Forecast to 2030

Introduction to the Evolving Landscape of Menopausal Symptom Management

Emerging Paradigm Shifts Reshaping Treatment Modalities

Navigating the Effects of 2025 United States Tariff Policies

Uncovering Core Patient and Product Segmentation Dynamics

Regional Market Nuances Driving Strategic Priorities

Evaluating Leading Players and Competitive Strategies

Strategic Recommendations to Capitalize on Market Opportunities

Robust Methodological Framework Underpinning the Analysis

Synthesizing Insights to Inform Decision Making

Market Segmentation & Coverage

Table of Contents

Companies Mentioned

Methodology

Table Information

Introduction to the Evolving Landscape of Menopausal Symptom Management

Emerging Paradigm Shifts Reshaping Treatment Modalities

Navigating the Effects of 2025 United States Tariff Policies

Uncovering Core Patient and Product Segmentation Dynamics

Regional Market Nuances Driving Strategic Priorities

Evaluating Leading Players and Competitive Strategies

Strategic Recommendations to Capitalize on Market Opportunities

Robust Methodological Framework Underpinning the Analysis

Synthesizing Insights to Inform Decision Making

Market Segmentation & Coverage

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Menopausal Hot Flashes Market Report 2025

Menopausal Hot Flash Market Report: Trends, Forecast and Competitive Analysis to 2031

Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2025

Post Menopausal Osteoporosis - Market Insight, Epidemiology and Market Forecast - 2034

Women Reproductive Health Market (2024 Edition): Analysis By Treatment Type (Menstrual Disorder, Uterine Fibroids/ Endometriosis, Infertility, Menopausal Disorder), By Route of Administration, By End User, By Region: Market Insights and Forecast (2020-2030)

About the Hot Flashes Market